Association between interleukin‑36γ and tumor progression in non‑small cell lung cancer

Liu,Lin; He,Honghong; Xu,Dan; Feng,Yuehua; Zhou,Huijun; Shi,Liyan; Gu,Yanzheng; Wang,Jian; Zhu,Yibei

doi:10.3892/ol.2020.11319

Association between interleukin‑36γ and tumor progression in non‑small cell lung cancer

Authors:
- Lin Liu
- Honghong He
- Dan Xu
- Yuehua Feng
- Huijun Zhou
- Liyan Shi
- Yanzheng Gu
- Jian Wang
- Yibei Zhu
View Affiliations

Affiliations: Department of Immunology, School of Biology and Basic Medical Sciences, Soochow University, Suzhou, Jiangsu 215123, P.R. China, Comprehensive Laboratory, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, P.R. China, Jiangsu Key Laboratory of Clinical Immunology, Soochow University, Suzhou, Jiangsu 215006, P.R. China, Institute of Pediatric Research, Children's Hospital of Soochow University, Suzhou, Jiangsu 215025, P.R. China
Published online on: January 17, 2020 https://doi.org/10.3892/ol.2020.11319
Pages: 2457-2465
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Immunotherapy is effective in improving the survival and prognosis of patients with non‑small cell lung cancer (NSCLC), and identifying effective immunomarkers is important for immunotherapy. Interleukin (IL)‑36γ is a novel immunomarker that has an important function in the antitumor immune response. The present study investigated the association between IL‑36γ and NSCLC to provide novel insight into immunotherapy for patients with NSCLC. Tissue microarrays of lung adenocarcinoma and squamous cell carcinoma were purchased for immunohistochemical analysis of IL‑36γ expression levels and clinical parameters. In addition, fresh clinical NSCLC and adjacent normal tissue samples were collected to analyze IL‑36γ mRNA expression levels using quantitative PCR. IL‑36γ protein was primarily located in the cytoplasm, with a small quantity in the nucleus, and IL‑36γ mRNA and protein expression levels in lung cancer tissues were significantly higher compared with those in adjacent normal tissues. Elevated IL‑36γ protein expression levels were significantly associated with a higher tumor grade of lung adenocarcinoma; however, IL‑36γ mRNA expression levels were inversely associated with the clinical Tumor‑Node‑Metastasis stage in patients with lung squamous cell carcinoma. In addition, patients with adenocarcinoma with high IL‑36γ protein expression levels tended to longer post‑operative survival times. These findings indicate that IL‑36γ may have potential as an immunomarker for prediction of tumor progression and survival in patients with NSCLC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Miura Y and Sunaga N: Role of immunotherapy for oncogene-driven non-small cell lung cancer. Cancers (Basel). 10:E2452018. View Article : Google Scholar : PubMed/NCBI
3	Burnet M: Cancer; A biological approach. I. The processes of control. Br Med J. 1:779–786. 1957. View Article : Google Scholar : PubMed/NCBI
4	Schreiber RD, Old LJ and Smyth MJ: Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science. 331:1565–1570. 2011. View Article : Google Scholar : PubMed/NCBI
5	Sugie T: Immunotherapy for metastatic breast cancer. Chin Clin Oncol. 7:282018. View Article : Google Scholar : PubMed/NCBI
6	Mellman I, Coukos G and Dranoff G: Cancer immunotherapy comes of age. Nature. 480:480–489. 2011. View Article : Google Scholar : PubMed/NCBI
7	Wang X, Zhao X, Feng C, Weinstein A, Xia R, Wen W, Lv Q, Zuo S, Tang P, Yang X, et al: IL-36γ transforms the tumor microenvironment and promotes type 1 lymphocyte-mediated antitumor immune responses. Cancer Cell. 28:296–306. 2015. View Article : Google Scholar : PubMed/NCBI
8	Lippitz BE: Cytokine patterns in patients with cancer: A systematic review. Lancet Oncol. 14:e218–228. 2013. View Article : Google Scholar : PubMed/NCBI
9	Gresnigt MS and van de Veerdonk FL: Biology of IL-36 cytokines and their role in disease. Semin Immunol. 25:458–465. 2013. View Article : Google Scholar : PubMed/NCBI
10	Bassoy EY, Towne JE and Gabay C: Regulation and function of interleukin-36 cytokines. Immunol Rev. 281:169–178. 2018. View Article : Google Scholar : PubMed/NCBI
11	Qin X, Liu M, Zhang S, Wang C and Zhang T: The role of IL-36γ and its regulation in eosinophilic inflammation in allergic rhinitis. Cytokine. 117:84–90. 2019. View Article : Google Scholar : PubMed/NCBI
12	Ramadas RA, Li X, Shubitowski DM, Samineni S, Wills-Karp M and Ewart SL: IL-1 receptor antagonist as a positional candidate gene in a murine model of allergic asthma. Immunogenetics. 58:851–855. 2006. View Article : Google Scholar : PubMed/NCBI
13	Blumberg H, Dinh H, Trueblood ES, Pretorius J, Kugler D, Weng N, Kanaly ST, Towne JE, Willis CR, Kuechle MK, et al: Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J Exp Med. 204:2603–2614. 2007. View Article : Google Scholar : PubMed/NCBI
14	Johnston A, Xing X, Guzman AM, Riblett M, Loyd CM, Ward NL, Wohn C, Prens EP, Wang F, Maier LE, et al: IL-1F5, -F6, -F8, and -F9: A novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J Immunol. 186:2613–2622. 2011. View Article : Google Scholar : PubMed/NCBI
15	Chustz RT, Nagarkar DR, Poposki JA, Favoreto S Jr, Avila PC, Schleimer RP and Kato A: Regulation and function of the IL-1 family cytokine IL-1F9 in human bronchial epithelial cells. Am J Respir Cell Mol Biol. 45:145–153. 2011. View Article : Google Scholar : PubMed/NCBI
16	Gresnigt MS, Rosler B, Jacobs CW, Becker KL, Joosten LA, van der Meer JW, Netea MG, Dinarello CA and van de Veerdonk FL: The IL-36 receptor pathway regulates aspergillus fumigatus-induced Th1 and Th17 responses. Eur J Immunol. 43:416–426. 2013. View Article : Google Scholar : PubMed/NCBI
17	Vigne S, Palmer G, Martin P, Lamacchia C, Strebel D, Rodriguez E, Olleros ML, Vesin D, Garcia I, Ronchi F, et al: IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4⁺ T cells. Blood. 120:3478–3487. 2012. View Article : Google Scholar : PubMed/NCBI
18	Weinstein AM, Chen L, Brzana EA, Patil PR, Taylor JL, Fabian KL, Wallace CT, Jones SD, Watkins SC, Lu B, et al: Tbet and IL-36γ cooperate in therapeutic DC-mediated promotion of ectopic lymphoid organogenesis in the tumor microenvironment. Oncoimmunology. 6:e13222382017. View Article : Google Scholar : PubMed/NCBI
19	Yang M, Feng Y, Yue C, Xu B, Chen L, Jiang J, Lu B and Zhu Y: Lower expression level of IL-33 is associated with poor prognosis of pulmonary adenocarcinoma. PLoS One. 13:e01934282018. View Article : Google Scholar : PubMed/NCBI
20	Feng SH and Yang ST: The new 8th TNM staging system of lung cancer and its potential imaging interpretation pitfalls and limitations with CT image demonstrations. Diagn Interv Radiol. 25:270–279. 2019. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Chen C, Qu QX, Xie F, Zhu WD, Zhu YH and Huang JA: Analysis of B7-H4 expression in metastatic pleural adenocarcinoma and therapeutic potential of its antagonists. BMC Cancer. 17:6522017. View Article : Google Scholar : PubMed/NCBI
23	Sun J, Chen LJ, Zhang GB, Jiang JT, Zhu M, Tan Y, Wang HT, Lu BF and Zhang XG: Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma. Cancer Immunol Immunother. 59:1163–1171. 2010. View Article : Google Scholar : PubMed/NCBI
24	Liew FY, Pitman NI and McInnes IB: Disease-associated functions of IL-33: The new kid in the IL-1 family. Nat Rev Immunol. 10:103–110. 2010. View Article : Google Scholar : PubMed/NCBI
25	Li X, Lv Q, Feng Y, Gu Y, Xia R, Ma J, He H and Zhu Y: Interleukin-33, a potential cytokine expressed in tumor microenvironment involves in antitumor immunotherapy through facilitates CD8(+) T cells. J Interferon Cytokine Res. 38:491–499. 2018. View Article : Google Scholar : PubMed/NCBI
26	Zhao X, Chen X, Shen X, Tang P, Chen C, Zhu Q, Li M, Xia R, Yang X, Feng C, et al: IL-36β promotes CD8(+) T cell activation and antitumor immune responses by activating mTORC1. Front Immunol. 10:18032019. View Article : Google Scholar : PubMed/NCBI
27	Boutet MA, Bart G, Penhoat M, Amiaud J, Brulin B, Charrier C, Morel F, Lecron JC, Rolli-Derkinderen M, Bourreille A, et al: Distinct expression of interleukin (IL)-36α, β and γ, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease. Clin Exp Immunol. 184:159–173. 2016. View Article : Google Scholar : PubMed/NCBI
28	Tomuschat C, O'Donnell AM, Coyle D and Puri P: Altered expression of IL36γ and IL36 receptor (IL1RL2) in the colon of patients with Hirschsprung's disease. Pediatr Surg Int. 33:181–186. 2017. View Article : Google Scholar : PubMed/NCBI
29	Gardner JK and Herbst-Kralovetz MM: IL-36γ induces a transient HSV-2 resistant environment that protects against genital disease and pathogenesis. Cytokine. 111:63–71. 2018. View Article : Google Scholar : PubMed/NCBI
30	Xiaoling Y, Chao W, Wenming W, Feng L and Hongzhong J: Interleukin (IL)-8 and IL-36γ but not IL-36Ra are related to acrosyringia in pustule formation associated with palmoplantar pustulosis. Clin Exp Dermatol. 44:52–57. 2019. View Article : Google Scholar : PubMed/NCBI
31	Wein AN, Dunbar PR, McMaster SR, Li ZT, Denning TL and Kohlmeier JE: IL-36γ protects against severe influenza infection by promoting lung alveolar macrophage survival and limiting viral replication. J Immunol. 201:573–582. 2018. View Article : Google Scholar : PubMed/NCBI
32	Chen Y, Sun J, Huang Y, Liu Y, Liang L, Yang D, Lu B and Li S: Targeted codelivery of doxorubicin and IL-36γ expression plasmid for an optimal chemo-gene combination therapy against cancer lung metastasis. Nanomedicine. 15:129–141. 2019. View Article : Google Scholar : PubMed/NCBI
33	Huynh J, Scholz GM, Aw J, Kwa MQ, Achuthan A, Hamilton JA and Reynolds EC: IRF6 regulates the expression of IL-36γ by human oral epithelial cells in response to porphyromonas gingivalis. J Immunol. 196:2230–2238. 2016. View Article : Google Scholar : PubMed/NCBI
34	Foster AM, Baliwag J, Chen CS, Guzman AM, Stoll SW, Gudjonsson JE, Ward NL and Johnston A: IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin. J Immunol. 192:6053–6061. 2014. View Article : Google Scholar : PubMed/NCBI
35	Vigne S, Palmer G, Lamacchia C, Martin P, Talabot-Ayer D, Rodriguez E, Ronchi F, Sallusto F, Dinh H, Sims JE and Gabay C: IL-36R ligands are potent regulators of dendritic and T cells. Blood. 118:5813–5823. 2011. View Article : Google Scholar : PubMed/NCBI